METHODS AND COMPOSITIONS FOR CORRECTION OF CARDIAC CONDUCTION DISTURBANCES
The invention provides methods for establishing electrical coupling between cardiomyocytes and recombinant cells which have been genetically engineered to express a gap junction protein, e.g., a connexin protein such as connexin 43 (Cx43) protein. The invention is based on the discovery that genetic modification of skeletal muscle cells to express a recombinant connexin, enables the genetically modified cells to establish electrocommunication with cardiac cells via gap junctions. The recombinant connexin expressing cells can be used for repair of cardiac tissue and for treatment of cardiac disease by transplantation into cardiac tissue.
1 . A method of establishing an electrical connection between a recombinant mammalian cell and a myocardial cell, the method comprising:
contacting a myocardial cell with a recombinant mammalian cell genetically modified to produce a connexin protein, said contacting being in a manner sufficient to provide for production of an electrical connection between the myocardial cell and the recombinant cell;
wherein an electrical connection between the recombinant cell and the myocardial cell is established.
2 . The method of claim 1 , wherein the recombinant cell is selected from the group consisting of a skeletal muscle cell, a stem cell, a fibroblast, and a cardiac cell.
3 . The method of claim 1 , wherein the recombinant cell is a skeletal muscle cell.
4 . The method of claim 3 , wherein the skeletal muscle cell is an adult skeletal muscle cell.
5 . The method of claim 3 , wherein the skeletal muscle cell is a myoblast cell.
6 . The method of claim 1 , wherein the connexin protein is a connexin 43 protein.
7 . A method of claim 1 , wherein said contacting comprises implanting the recombinant cell into myocardial tissue of a subject.
8 . The method of claim 1 , wherein after the electrical connection between the recombinant cell and the myocardial cell is established, the recombinant cell has similar conductive characteristics similar to the myocardial cell.
9 . A method of establishing an electrical connection between a recombinant skeletal muscle cell and a myocardial cell, the method comprising:
contacting a myocardial cell with a recombinant skeletal muscle cell genetically modified to express a connexin protein, said contacting being in a manner sufficient to provide for production of an electrical connection between the myocardial cell and the recombinant skeletal muscle cell;
wherein an electrical connection between the recombinant skeletal muscle cell and the myocardial cell is established.
10 . The method of claim 9 , wherein the skeletal muscle cell is an adult skeletal muscle cell.
11 . The method of claim 9 , wherein the skeletal muscle cell is a skeletal myoblast cell.
12 . The method of claim 9 , wherein after the electrical connection between the recombinant cell and the myocardial cell is established, the recombinant cell has similar conductive characteristics as the myocardial cell.
13 . A method of establishing an electrical connection between a recombinant skeletal muscle cell and a myocardial cell, the method comprising:
contacting a myocardial cell with a recombinant skeletal myoblast cell genetically modified to express a recombinant connexin 43 protein, said contacting being in a manner sufficient to provide for production of an electrical connection between the myocardial cell and the recombinant skeletal myoblast cell;
wherein an electrical connection between the recombinant skeletal myoblast cell and the myocardial cell is established so that the recombinant skeletal myoblast cell has similar conductive characteristics as the myocardial cell.
14 . A method for treating a cardiac conduction disturbance in a host, the method comprising:
introducing into cardiac tissue of a host a therapeutically effective amount of a recombinant mammalian cell, which recombinant cell is genetically modified to express a connexin protein, said introducing being effective to establish an electrical connection between the recombinant cell and a myocardial cell of the host cardiac tissue;
wherein the cardiac conduction disturbance in the host is treated.
15 . The method of claim 14 , wherein the recombinant cell is selected from the group consisting of a skeletal muscle cell, a stem cell, a fibroblast, and a cardiac cell.
16 . The method of claim 14 , wherein the recombinant cell is a skeletal muscle cell.
17 . The method of claim 16 , wherein the skeletal muscle cell is an adult skeletal muscle cell.
18 . The method of claim 16 , wherein the skeletal muscle cell is a myoblast cell.
19 . The method of claim 14 , wherein the connexin protein is a connexin 43 protein.
20 . The method of claim 14 , wherein said introducing comprises implanting the recombinant cell into an infarct region of the cardiac tissue.
21 . The method of claim 14 , wherein the recombinant cell is autologus to the host.
22 . A method for treating a cardiac conduction disturbance in a mammalian host, the method comprising:
introducing into cardiac tissue of the host a therapeutically effective amount of a skeletal muscle cell genetically modified to express a connexin 43 protein, said introducing being effective to establish an electrical connection between the introduced recombinant skeletal muscle cell and a myocardial cell of the host cardiac tissue;
wherein the cardiac conduction disturbance is treated.
23 . The method of claim 22 , wherein the skeletal muscle cell is an adult skeletal muscle cell.
24 . A method of claim 22 , wherein the skeletal muscle cell is a myoblast cell.
25 . The method of claim 22 , wherein said introducing comprises implanting the recombinant cell into an infarct region of the cardiac tissue.
26 . The method of claim 22 , wherein the recombinant skeletal muscle cell is autologus to the host.